SecBot SecBot
SECBOTREPLAY Home › Report › RDY

RDY · Dr

DR REDDYS LABORATORIES LTD · 6-K filed Sep 14, 2026 at 06:35 ET

At the news

NEUTRALIMPACT 3/10

6-K filed Sep 14, 2026 at 06:35 ET

Dr. Reddy's disclosed that the USFDA completed a records assessment at its API manufacturing facility in Mexico (Jiutepec, Morelos) between July 17 and September 8, 2026, issuing a Form FDA 2953 with two observations. The company will respond within the stipulated timeline. This is a routine regulatory follow-up with no material financial impact disclosed, and the two observations are not quantified or characterized as critical.

  • USFDA conducted a records assessment under Section 704(a)(4) at Dr. Reddy's API facility in Mexico (Industrias Químicas Falcón de México, S.A. de C.V.) from July 17 to September 8, 2026.
  • The USFDA issued a Form FDA 2953 containing two observations; the company will respond within the stipulated timeline.
  • No warning letter, shutdown, import alert, or material financial impact was disclosed in the filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access